Immunologic Tests
Conditions
Keywords
Immunological assays, Chronic hepatitis B
Brief summary
The purpose of this study is to develop and characterize immunological assays on blood samples.
Interventions
OTHERBlood withdrawal
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent obtained from the subject. * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * A male or female between, and including, 18 and 65 years of age at study start. * Evidence of chronic hepatitis B infection as per medical record. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start. In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records: Group A: Immune tolerant patients * Viral load: \> 2x107 IU/mL of HBV DNA * HBeAg positive * Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients * Viral load: \> 2x104 IU/mL of HBV DNA * HBeAg positive * Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers * Viral load: not exceeding 2x103 IU/mL of HBV DNA * HBeAg negative * Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients * Viral load: \> 2x103 IU/mL of HBV DNA * HBeAg negative * Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy
Exclusion criteria
* Any hepatitis B specific treatment prior to blood sampling at Visit 1. * Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol. * Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1. * Receipt of blood products within 120 days prior to study entry (Visit 1). * Receipt of immunoglobulins within 120 days prior to study entry (Visit 1). * Receipt of interferon within 120 days prior to study entry (Visit 1). * Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required). * Pregnant or lactating female. * History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period). * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed. * History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible). * History of major congenital defect. * Subjects with a history of, or current, alcohol or substance abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3. |
| Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3. |
| Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3. |
| Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3. |
| Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3. |
| Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3. |
| Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3. |
| Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67. |
| Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67. |
| Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3. |
| Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3. |
| Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3. |
| Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
| Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
| Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
| Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | At the time of the visit for each subject (i.e., Day 0) | The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
Countries
Belgium
Participant flow
Recruitment details
The study period (i.e., from study initiation until study completion) was approximately 22 months (i.e., from April-2010 until February-2012). The duration of the study was one day for each subject.
Pre-assignment details
All 99 subjects enrolled in the study were included in the analysis.
Participants by arm
| Arm | Count |
|---|---|
| Immune Tolerant Patients Group Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings. | 7 |
| HBeAg Positive Group HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis. | 11 |
| Inactive Carriers Group Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis. | 60 |
| HBeAg Negative Group HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis. | 21 |
| Total | 99 |
Baseline characteristics
| Characteristic | Immune Tolerant Patients Group | Total | HBeAg Negative Group | Inactive Carriers Group | HBeAg Positive Group |
|---|---|---|---|---|---|
| Age, Continuous | 26.4 Years STANDARD_DEVIATION 6 | 36.43 Years STANDARD_DEVIATION 11.19 | 39.7 Years STANDARD_DEVIATION 15.1 | 36.9 Years STANDARD_DEVIATION 8.7 | 34.0 Years STANDARD_DEVIATION 14.2 |
| Race/Ethnicity, Customized Geographic Ancestry African heritage/African American | 5 Participants | 47 Participants | 9 Participants | 31 Participants | 2 Participants |
| Race/Ethnicity, Customized Geographic Ancestry Asian-Central/South Asian heritage | 0 Participants | 3 Participants | 0 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Geographic Ancestry Asian-East Asian heritage | 1 Participants | 5 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Geographic Ancestry Other: Kazakstan | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Geographic Ancestry Other: Latino | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Geographic Ancestry White-Arabic/North African heritage | 0 Participants | 18 Participants | 7 Participants | 11 Participants | 0 Participants |
| Race/Ethnicity, Customized Geographic Ancestry White-Caucasian/European heritage | 0 Participants | 24 Participants | 4 Participants | 15 Participants | 5 Participants |
| Sex: Female, Male Female | 3 Participants | 37 Participants | 5 Participants | 25 Participants | 4 Participants |
| Sex: Female, Male Male | 4 Participants | 62 Participants | 16 Participants | 35 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 11 | 0 / 60 | 0 / 21 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 7 | 0 / 11 | 0 / 60 | 0 / 21 |
Outcome results
Primary
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L- | 1.2035 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L+ | 32.2 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+polypositives FOXP3-CCR7+CD45RA+CD62L | 44.45 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L- | 7.795 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD62L+ | 83.6 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L- | 5.79 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA+CD62L- | 0.4295 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+ | 83.2 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L+ | 7.91 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L+ | 1.005 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3- | 95.9 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD45RA+ | 47.45 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+ | 79.5 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L- | 1.72 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3- | 94.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L- | 9.79 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L+ | 6.69 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA+CD62L- | 0.474 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD62L+ | 85 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L+ | 26.7 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+polypositives FOXP3-CCR7+CD45RA+CD62L | 39.7 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L- | 4.09 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD45RA+ | 47.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L+ | 0.755 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L- | 10.54 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3- | 95.73 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+ | 76.1 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA+CD62L- | 0.305 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L+ | 34.7 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L- | 4.35 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L+ | 0.719 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L- | 0.82 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L+ | 8.86 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD45RA+ | 38.6 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD62L+ | 83.6 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+polypositives FOXP3-CCR7+CD45RA+CD62L | 35.56 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L- | 15.5 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L+ | 1.01 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L- | 5.16 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3- | 95.4 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD45RA+ | 33.8 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA-CD62L+ | 33.4 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+CD45RA+CD62L- | 0.272 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+polypositives FOXP3-CCR7+CD45RA+CD62L | 32.1 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7+ | 70.8 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA-CD62L+ | 10.84 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CCR7-CD45RA+CD62L- | 0.855 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L | CD4+FOXP3-CD62L+ | 75.3 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2- | 41.85 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2+ | 30.2 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2- | 22.9 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+polypositives FOXP3-CD39+CD45RA+TNFR2 | 0.3485 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA+TNFR2- | 0.828 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3- | 94.65 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2+ | 1.965 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-TNFR2+ | 35.05 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2- | 0.6185 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+ | 3.395 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2+ | 2.66 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD45RA+ | 45.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-TNFR2+ | 34.1 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2- | 40.9 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3- | 94.3 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2- | 20 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2+ | 2.55 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2+ | 29.6 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2+ | 2.25 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+polypositives FOXP3-CD39+CD45RA+TNFR2 | 0.252 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD45RA+ | 48 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+ | 3.93 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA+TNFR2- | 0.531 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2- | 0.754 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2+ | 32.155 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3- | 95.585 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+ | 4.015 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA+TNFR2- | 0.5295 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2+ | 2.22 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2- | 0.6635 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2+ | 3.585 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2- | 36.41 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2- | 21.42 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD45RA+ | 41.235 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-TNFR2+ | 39.23 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+polypositives FOXP3-CD39+CD45RA+TNFR2 | 0.2795 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2+ | 3.04 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2- | 0.749 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3- | 94.7 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD45RA+ | 33.8 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA-TNFR2+ | 3.24 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+CD45RA+TNFR2- | 0.46 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+polypositives FOXP3-CD39+CD45RA+TNFR2 | 0.336 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-TNFR2+ | 45.6 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2+ | 38.9 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA+TNFR2- | 29.9 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39+ | 4.83 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2 | CD4+FOXP3-CD39-CD45RA-TNFR2- | 20.9 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD45RA+ | 17 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+pol FOXP3+CD39+CD45RA+TNFR2 | 1.2415 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2+ | 35.25 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+ | 5.375 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2- | 0.8705 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA+TNFR2- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2+ | 45.55 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+ | 47.25 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+TNFR2+ | 97.7 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2- | 0.48 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2+ | 14.8 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2- | 1.009 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+ | 54.7 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2- | 0.7245 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2+ | 37.3 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2- | 0.6765 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD45RA+ | 13.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2+ | 25.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+ | 5.68 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2+ | 11 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2- | 0.165 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA+TNFR2- | 0.0156 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+pol FOXP3+CD39+CD45RA+TNFR2 | 1.49 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+TNFR2+ | 98.4 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2+ | 37.685 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+ | 4.415 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+ | 42.2 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA+TNFR2- | 0.0381 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2+ | 39.85 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2- | 0.1915 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2+ | 17.075 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2- | 0.815 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2- | 1.085 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD45RA+ | 19.75 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+TNFR2+ | 97.25 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+pol FOXP3+CD39+CD45RA+TNFR2 | 1.215 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2+ | 13.12 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2- | 0.32 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+ | 5.32 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD45RA+ | 15.7 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA-TNFR2+ | 43.3 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+CD45RA+TNFR2- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+pol FOXP3+CD39+CD45RA+TNFR2 | 0.9295 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+TNFR2+ | 97.9 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2+ | 32.01 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA+TNFR2- | 0.658 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39+ | 46.9 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2) | CD4+FOXP3+CD39-CD45RA-TNFR2- | 0.702 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD45RA+ | 14.8 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+polypositives FOXP3+CCR7+CD45RA+CD62L | 14.25 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L+ | 43.3 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+ | 4.12 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L- | 9.6 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA+CD62L- | 0.4295 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L+ | 27.85 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+ | 44.15 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD62L+ | 88.55 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L- | 1.73 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L+ | 0.909 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L- | 0.0502 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+ | 48.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L- | 0.0732 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L+ | 30.1 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L- | 13.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD45RA+ | 14 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L+ | 36.6 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+ | 5.48 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L+ | 0.522 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L- | 3.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA+CD62L- | 0.2005 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+polypositives FOXP3+CCR7+CD45RA+CD62L | 11.3 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD62L+ | 81.5 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L+ | 37.7 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+ | 4.26 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+ | 54.065 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA+CD62L- | 0.11 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L+ | 34.66 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L- | 1.88 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L+ | 0.59 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L- | 0.0499 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L- | 6.56 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD45RA+ | 16.95 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD62L+ | 90.85 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+polypositives FOXP3+CCR7+CD45RA+CD62L | 15.1 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L+ | 0.8925 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L- | 2.065 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+ | 4.64 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD45RA+ | 14.25 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA-CD62L+ | 25.65 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+CD45RA+CD62L- | 0.105 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+polypositives FOXP3+CCR7+CD45RA+CD62L | 11.95 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CD62L+ | 88.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L+ | 42.5 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA+CD62L- | 0.075 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7+ | 42.4 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L | CD4+FOXP3+CCR7-CD45RA-CD62L- | 8.985 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CTLA4+ | 3.825 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3-CD45RA+CTLA4+OX40 | 0.0488 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40+ | 3.035 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3- | 94.45 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40- | 41.25 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4+OX40- | 0.2755 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40+ | 0.1715 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+ | 45.2 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-OX40+ | 5.235 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40- | 44.55 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40+ | 0.508 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40- | 2.35 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+ | 46.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40- | 1.87 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40+ | 0.287 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40- | 51.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CTLA4+ | 2.34 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40+ | 2.48 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3- | 93.9 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40+ | 0.242 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40- | 46 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4+OX40- | 0.263 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3-CD45RA+CTLA4+OX40 | 0.0366 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-OX40+ | 3.23 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40+ | 1.78 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3- | 95.395 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+ | 36.05 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4+OX40- | 0.2505 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40+ | 0.1645 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40- | 34.4 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40+ | 0.2645 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40- | 2.39 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40- | 53.05 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CTLA4+ | 3.4 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-OX40+ | 2.27 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3-CD45RA+CTLA4+OX40 | 0.0359 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40+ | 0.6175 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40- | 25.5 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3- | 94.95 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CTLA4+ | 3.55 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4-OX40+ | 0.243 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+CTLA4+OX40- | 0.265 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3-CD45RA+CTLA4+OX40 | 0.0646 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-OX40+ | 5.675 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40+ | 4.015 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4+OX40- | 1.845 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA+ | 31.55 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3-CD45RA-CTLA4-OX40- | 56.05 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CTLA4+ | 31.8 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3+CD45RA+CTLA4+OX40 | 0.188 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40+ | 8.16 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+ | 5.555 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40- | 43.9 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4+OX40- | 1.5 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40+ | 0.107 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+ | 17.8 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+OX40+ | 10.1 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40- | 15.9 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40+ | 1.73 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40- | 28.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+ | 17.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40- | 41 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40+ | 0.174 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40- | 42 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CTLA4+ | 45 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40+ | 1.915 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+ | 6.09 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40+ | 2.08 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40- | 15.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4+OX40- | 1.75 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3+CD45RA+CTLA4+OX40 | 0.118 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+OX40+ | 5.15 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40+ | 1.515 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+ | 4.655 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+ | 18.5 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4+OX40- | 1.32 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40+ | 0.11 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40- | 16.1 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40+ | 1.345 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40- | 24.5 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40- | 47.9 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CTLA4+ | 27.5 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+OX40+ | 3.66 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3+CD45RA+CTLA4+OX40 | 0.19 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40+ | 2.38 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40- | 13.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+ | 5.045 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CTLA4+ | 39.3 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4-OX40+ | 0.126 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+CTLA4+OX40- | 1.09 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+polypositives FOXP3+CD45RA+CTLA4+OX40 | 0.283 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+OX40+ | 3.94 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40+ | 1.39 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4+OX40- | 31.7 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA+ | 16.6 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40 | CD4+FOXP3+CD45RA-CTLA4-OX40- | 38.1 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-GITR+ | 15.05 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67+ | 1.575 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67- | 37.5 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+polypositives FOXP3-CD45RA+GITR+KI67 | 0.1275 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR+KI67- | 0.6515 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3- | 94.65 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67+ | 0.328 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-KI67+ | 3.18 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67- | 42.85 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67+ | 1.0535 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+ | 45.95 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67- | 13.35 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67- | 42.5 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67- | 12.6 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+ | 42.9 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67- | 43.7 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-KI67+ | 3.42 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67+ | 1.56 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67+ | 0.365 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+polypositives FOXP3-CD45RA+GITR+KI67 | 0.0944 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3- | 94.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-GITR+ | 14 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67+ | 0.566 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR+KI67- | 0.567 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67+ | 1.83 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67+ | 0.251 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3- | 95.31 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+ | 34.3 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR+KI67- | 0.609 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67- | 30.14 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67+ | 0.854 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67- | 12.94 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67- | 49.1 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-GITR+ | 15.9 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-KI67+ | 3.32 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+polypositives FOXP3-CD45RA+GITR+KI67 | 0.0945 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67+ | 0.7955 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67- | 30.3 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3- | 94.65 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-GITR+ | 15.7 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR-KI67+ | 0.2275 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+GITR+KI67- | 0.563 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+polypositives FOXP3-CD45RA+GITR+KI67 | 0.0901 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-KI67+ | 3.28 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67+ | 1.455 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR+KI67- | 13.225 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA+ | 33.4 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67 | CD4+FOXP3-CD45RA-GITR-KI67- | 50.9 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+GITR+ | 46.4 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+polypositives FOXP3+CD45RA+GITR+KI67 | 0.2685 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67+ | 4.84 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+ | 5.335 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67- | 30.9 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR+KI67- | 0.2955 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67+ | 0.0985 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+ | 12.85 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+KI67+ | 13.95 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67- | 12.55 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67+ | 9.26 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67- | 35.65 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+ | 14.8 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67- | 33.4 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67+ | 0.2085 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67- | 32.3 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+GITR+ | 49.1 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67+ | 3.66 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+ | 5.82 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67+ | 8.24 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67- | 13.8 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR+KI67- | 0.429 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+polypositives FOXP3+CD45RA+GITR+KI67 | 0.1855 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+KI67+ | 14.2 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67+ | 4.69 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+ | 4.68 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+ | 18.2 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR+KI67- | 0.49 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67+ | 0.234 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67- | 17.7 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67+ | 8.14 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67- | 27.34 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67- | 37.1 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+GITR+ | 38.5 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+KI67+ | 13.8 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+polypositives FOXP3+CD45RA+GITR+KI67 | 0.331 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67+ | 7.43 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67- | 15.4 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+ | 5.37 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+GITR+ | 36.9 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR-KI67+ | 0.267 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+GITR+KI67- | 0.399 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+polypositives FOXP3+CD45RA+GITR+KI67 | 0.28 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+KI67+ | 12.7 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67+ | 4.27 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR+KI67- | 28.8 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA+ | 16.5 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67 | CD4+FOXP3+CD45RA-GITR-KI67- | 41.4 Treg cells/million cells |
Primary
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1+ | 1.935 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1+ | 1.065 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1+ | 8.21 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1- | 1.755 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1+ | 0.2825 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+polypositives FOXP3-CD45RA+HLADR+ICOS+PD1 | 0.0998 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1- | 7.985 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3- | 94.95 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-PD1+ | 14.6 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1- | 1.53 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+ | 38.7 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1+ | 0.0895 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-ICOS+ | 14.6 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1- | 1.33 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1+ | 0.174 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-HLADR+ | 7.845 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1- | 32.15 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS+PD1- | 0.0995 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1+ | 1.37 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1- | 35.6 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1- | 1.515 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1+ | 0.0928 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1+ | 6.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+ | 44.3 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1+ | 0.8265 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-PD1+ | 9.895 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1- | 36.95 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS+PD1- | 0.1103 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1- | 0.979 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1- | 1.84 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1- | 8.835 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3- | 93.75 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1+ | 2.28 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1+ | 0.1695 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-HLADR+ | 6.22 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1- | 27.95 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1+ | 0.193 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+polypositives FOXP3-CD45RA+HLADR+ICOS+PD1 | 0.069 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1- | 1.52 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1- | 0.727 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-ICOS+ | 16.95 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1+ | 0.995 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS+PD1- | 0.0853 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3- | 95.88 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+ | 33.9 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1+ | 0.267 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1- | 1.71 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1+ | 0.0873 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1- | 0.973 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1+ | 0.2585 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1- | 23.8 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1+ | 1.026 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1- | 0.789 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1+ | 0.8765 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1- | 1.32 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1+ | 2.485 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1- | 7.965 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1+ | 7.385 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1- | 34.8 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-HLADR+ | 8.66 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-ICOS+ | 21.03 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-PD1+ | 14.17 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+polypositives FOXP3-CD45RA+HLADR+ICOS+PD1 | 0.0689 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1+ | 14.1 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1+ | 0.994 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1- | 14.96 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-PD1+ | 20.3 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS-PD1- | 37.7 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS-PD1+ | 0.368 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1- | 0.357 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3- | 95 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-HLADR+ | 7.65 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR-ICOS+PD1+ | 0.0976 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1- | 1.07 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+ | 30.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-ICOS+ | 12.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS-PD1+ | 0.232 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1+ | 3.02 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1- | 0.989 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA+HLADR+ICOS+PD1- | 0.0297 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR-ICOS+PD1- | 5.95 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS-PD1+ | 1.34 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+FOXP3-CD45RA-HLADR+ICOS+PD1- | 0.522 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1 | CD4+polypositives FOXP3-CD45RA+HLADR+ICOS+PD1 | 0.0431 Treg cells/million cells |
Primary
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ | 5.025 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+ | 16.7 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS+PD1- | 0.1299 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1+ | 0.1191 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1- | 0.9705 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1+ | 0.1836 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1- | 0.3915 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1+ | 0.0723 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1- | 14.8 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1+ | 0.629 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1- | 18.8 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1+ | 0.5645 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1- | 18.7 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1+ | 0.6269 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1- | 6.39 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1+ | 0.7075 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1- | 27.85 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+HLADR+ | 45.4 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ICOS+ | 28 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+PD1+ | 5.505 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+polypositives FOXP3+CD45RA+HLADR+ICOS+PD1 | 0.1167 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+HLADR+ | 25.75 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ | 6.275 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1+ | 0.1245 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1+ | 0.478 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1- | 0.356 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1+ | 2.07 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1- | 9.66 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1- | 5.065 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS+PD1- | 0.0702 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+PD1+ | 8.465 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1- | 36.8 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1+ | 1.285 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1- | 14.2 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1- | 0.2905 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1+ | 0.0637 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+polypositives FOXP3+CD45RA+HLADR+ICOS+PD1 | 0.209 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1+ | 2.48 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1+ | 0.119 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+ | 16 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ICOS+ | 41.1 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1- | 13.35 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+ | 18 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1+ | 0.106 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1- | 0.74 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+HLADR+ | 31.65 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1+ | 0.0972 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1- | 15.985 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1+ | 1.85 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1- | 17.15 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ICOS+ | 33.795 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1+ | 0.651 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1- | 7.16 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+polypositives FOXP3+CD45RA+HLADR+ICOS+PD1 | 0.1645 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1+ | 1.26 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1- | 10.57 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+PD1+ | 6.98 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1+ | 1.815 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ | 4.185 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS+PD1- | 0.1755 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1- | 29.85 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1+ | 0.0762 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1- | 0.51 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1+ | 3.28 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1- | 14.86 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS-PD1- | 33.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ | 4.93 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+PD1+ | 9.61 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS+PD1+ | 2.03 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1- | 14.6 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+ | 16.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+HLADR+ | 36.6 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS-PD1+ | 0.138 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1+ | 0.092 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS+PD1- | 0.113 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+polypositives FOXP3+CD45RA+HLADR+ICOS+PD1 | 0.1935 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1+ | 1.96 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1- | 11.6 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+ICOS+ | 35.3 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR-ICOS+PD1- | 0.3185 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR-ICOS+PD1- | 9.79 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1- | 0.388 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA-HLADR+ICOS-PD1+ | 1.03 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1 | CD4+FOXP3+CD45RA+HLADR+ICOS-PD1+ | 0.0885 Treg cells/million cells |
Primary
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69-LAP+ | 0.74 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69-LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+LAP+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69-LAP+ | 0.055 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP- | 0.2 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+LAP+ | 0.29 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+ | 0.8 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69+LAP+ | 0.259 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples | CD4+FOXP3+CD69-LAP+ | 0.06 Treg cells/million cells |
Primary
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP- | 0.33 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP- | 0.45 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP- | 0.2501 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP+ | 0.0672 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP- | 0.1901 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-LAP+ | 0.0051 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP+ | 0.334 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-LAP+ | 0.2251 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+ | 0.16 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-LAP+ | 0.02 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP- | 0.15 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP+ | 0.025 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3- | 0.1 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-LAP+ | 0.0913 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP+ | 0.173 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP- | 0.1 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP+ | 0.1011 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+ | 0.28 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP+ | 0.01 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP- | 0.1 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-LAP+ | 0.0993 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP+ | 0.0165 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-LAP+ | 0.0345 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP- | 0.185 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+ | 0.068 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP+ | 0.046 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+ | 0.07 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+ | 0.25 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP+ | 0.0057 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69-LAP- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3-CD69+LAP- | 0.087 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP- | 0.279 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69-LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3-CD69+LAP+ | 0.0126 Treg cells/million cells |
Primary
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+ | 2.0101 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+ | 0.305 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP- | 0.6 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP+ | 0.049 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP- | 1.025 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+ | 0.35 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+LAP+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP+ | 0.5065 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP+ | 0.2201 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+LAP+ | 1.184 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+ | 0.21 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+ | 0.51 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+LAP+ | 0.02 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP- | 0.69 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP+ | 0.002 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+ | 0.25 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+ | 0.95 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+LAP+ | 0.07 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP- | 0.65 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP+ | 0.033 Treg cells/million cells |
| HBeAg Positive Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP+ | 0.0805 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+ | 0.84 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP+ | 0.082 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP- | 1.01 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+ | 0.42 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+LAP+ | 0.107 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+ | 0.0101 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP+ | 0.013 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+LAP+ | 0.04 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP- | 1.09 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+ | 0.905 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+ | 0.16 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP+ | 0.1335 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+ | 0.5315 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+LAP+ | 0.0476 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+ | 1.0115 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69-LAP- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBs CD4+FOXP3+CD69+LAP- | 0.5215 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP- | 0.9815 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+ | 0.52 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69-LAP+ | 0.0086 Treg cells/million cells |
| HBeAg Negative Group | Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples | HBc CD4+FOXP3+CD69+LAP+ | 0.0001 Treg cells/million cells |
Secondary
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+ | 0.0048 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0063 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.0048 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL17+ | 0.0063 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0161 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL2+ | 0.0161 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL2+ | 0.0128 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.105 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL17+ | 0.0012 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+ | 0.108 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0012 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0104 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+ | 0.0336 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL2+ | 0.0033 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL17+ | 0.0047 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.031 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0022 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0048 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL2+ | 0.0083 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+ | 0.032 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+IL17+ | 0.0037 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0039 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.031 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0083 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
Secondary
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IFNg+ | 0.0011 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0006 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.0158 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL17+ | 0.0128 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0023 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0038 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IFNg+ | 0.0164 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17+ | 0.0025 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+ | 0.0181 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL2+ | 0.0044 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL17+ | 0.0013 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL2+ | 0.0049 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0018 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17- | 0.0015 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+ | 0.0032 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL2+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL17+ | 0.0025 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.0023 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL2+ | 0.0064 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL17+ | 0.0058 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg-IL17+ | 0.0019 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL2+ | 0.0021 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IFNg+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL17+ | 0.0004 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+ | 0.0013 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17- | 0.0017 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.0013 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0025 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL2+ | 0.0014 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0012 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17- | 0.0041 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+ | 0.0053 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL2+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+IL17+ | 0.0002 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL17+ | 0.0014 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+ | 0.0135 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2+IFNg-IL17- | 0.0011 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+IL2+ | 0.0004 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17- | 0.0113 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBs CD4+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples | HBc CD4+CD40L-IL2-IFNg-IL17+ | 0.0022 Treg cells/million cells |
Secondary
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.1166 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IFNg+ | 0.0246 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL2+ | 0.0448 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0448 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL17+ | 0.1191 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0246 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0556 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+ | 0.0556 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL2+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IFNg+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL2+ | 0.0004 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL17+ | 0.0058 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0053 Treg cells/million cells |
| Inactive Carriers Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0058 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IFNg+ | 0.0002 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+ | 0.0035 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL17+ | 0.0075 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+IL2+ | 0.0042 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0075 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0035 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0002 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
Secondary
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).
Time frame: At the time of the visit for each subject (i.e., Day 0)
Population: The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available, who had satisfied all specific criteria according to their specific group and with data available for the markers analyzed within this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IFNg+ | 0.0167 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+ | 0.0046 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0039 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0251 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IFNg+ | 0.0346 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0034 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17- | 0.0046 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+ | 0.004 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17- | 0.0017 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17- | 0.0126 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL2+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL17+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL2+ | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Immune Tolerant Patients Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17+ | 0.0016 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+ | 0.0034 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IFNg+ | 0.003 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL2+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0052 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL2+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Positive Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL2+ | 0.0013 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IFNg+ | 0.0027 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL17+ | 0.0021 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg-IL17+ | 0.0026 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IFNg+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+ | 0.0002 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL17+ | 0.0015 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0002 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL2+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0021 Treg cells/million cells |
| Inactive Carriers Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17- | 0.0002 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+ | 0.0002 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IFNg+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IFNg+ | 0.0003 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL2+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+ | 0.0065 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+IL2+ | 0.001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17- | 0.0066 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg+IL17- | 0.0008 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg+IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L+IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBs CD8+CD40L-IL2+IFNg-IL17- | 0.0001 Treg cells/million cells |
| HBeAg Negative Group | Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples | HBc CD8+CD40L-IL2-IFNg-IL17+ | 0.0001 Treg cells/million cells |